checkAd

     105  0 Kommentare BeiGene Demonstrates Global Progress in 2023 Responsible Business & Sustainability Report - Seite 3

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding the future growth and global expansion of BeiGene; the ability of BeiGene to meet the goals set forth in its 2023 Responsible Business & Sustainability Report; and BeiGene’s plans, commitments, aspirations, and goals under the heading “About BeiGene.” Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeiGene's ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; BeiGene's ability to achieve commercial success for its marketed medicines and drug candidates, if approved; BeiGene's ability to obtain and maintain protection of intellectual property for its medicines and technology; BeiGene's reliance on third parties to conduct drug development, manufacturing, commercialization, and other services; BeiGene’s limited experience in obtaining regulatory approvals and commercializing pharmaceutical products; BeiGene’s ability to obtain additional funding for operations and to complete the development of its drug candidates and achieve and maintain profitability; and those risks more fully discussed in the section entitled “Risk Factors” in BeiGene’s most recent annual report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in BeiGene's subsequent filings with the U.S. Securities and Exchange Commission. All information in this press release is as of the date of this press release, and BeiGene undertakes no duty to update such information unless required by law.


    The BeiGene Stock at the time of publication of the news with a raise of +3,18 % to 153,3EUR on Nasdaq stock exchange (26. April 2024, 16:18 Uhr).
    Seite 3 von 3




    Business Wire (engl.)
    0 Follower
    Autor folgen

    Weitere Artikel des Autors


    BeiGene Demonstrates Global Progress in 2023 Responsible Business & Sustainability Report - Seite 3 BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, released its 2023 Responsible Business & Sustainability Report highlighting the Company’s strategy, the progress it has made towards existing goals, and how it …

    Schreibe Deinen Kommentar

    Disclaimer